Patents Assigned to ESBATech, an Alcon Biomedical Research Unit, LLC
-
Publication number: 20130053259Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.Type: ApplicationFiled: August 23, 2012Publication date: February 28, 2013Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT, LLC.Inventors: David M. Urech, Leonardo Borras
-
Publication number: 20130023652Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: Leonardo Borras, David Urech
-
Patent number: 8349322Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: June 25, 2009Date of Patent: January 8, 2013Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventors: Leonardo Borras, David Urech, Tea Gunde
-
Publication number: 20120288878Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.Type: ApplicationFiled: June 22, 2012Publication date: November 15, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: David Urech, Valerie Hulmann-Cottier
-
Patent number: 8293235Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: June 25, 2009Date of Patent: October 23, 2012Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventors: Leonardo Borras, David Urech
-
Patent number: 8280711Abstract: The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.Type: GrantFiled: March 12, 2008Date of Patent: October 2, 2012Assignee: ESBATech, an Alcon Biomedical Research Unit, LLC.Inventors: David M. Urech, Leonardo Borras
-
Patent number: 8227199Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.Type: GrantFiled: February 23, 2010Date of Patent: July 24, 2012Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventors: David Urech, Valerie Hulmann-Cottier
-
Publication number: 20120100153Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT, LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20120064077Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: September 26, 2011Publication date: March 15, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC.Inventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20120014958Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: June 25, 2009Publication date: January 19, 2012Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech, Tea Gunde
-
Patent number: 8067547Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: June 6, 2006Date of Patent: November 29, 2011Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20110268728Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.Type: ApplicationFiled: June 25, 2009Publication date: November 3, 2011Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech
-
Publication number: 20110200594Abstract: The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided.Type: ApplicationFiled: June 30, 2009Publication date: August 18, 2011Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventor: David Urech
-
Publication number: 20110159007Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: June 25, 2009Publication date: June 30, 2011Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: Leonardo Borras, Tea Gunde, David Urech
-
Publication number: 20110152505Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: ApplicationFiled: December 21, 2010Publication date: June 23, 2011Applicant: ESBATECH AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: David Urech, Tea Gunde, Leonardo Jose Borras
-
Publication number: 20110135644Abstract: The invention provides compositions and methods that enhance the delivery of large macromolecules (i.e., greater than 10 kDa), such as antigen-binding polypeptides, across tight junctions. Such methods and compositions are particularly useful for delivering therapeutic antigen-binding polypeptides to the CNS, via intranasal administration, for the treatment of neurological disorders.Type: ApplicationFiled: July 10, 2009Publication date: June 9, 2011Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: Valerie Hulmann-Cottier, David Urech, Esther Furrer
-
Publication number: 20110117091Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: ApplicationFiled: June 25, 2009Publication date: May 19, 2011Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: Leonardo Borras, David Urech
-
Publication number: 20110020912Abstract: An in vivo method for the construction of randomized gene libraries and/or domain replacement in gene libraries by homologous recombination using a Kluyveromyces lactis killer toxin, in particular the ?-subunit of the K. lactis killer toxin, as negative selection marker is described. The use of the ?-subunit of K. lactis as negative selectable marker increases the percentage of randomized clones.Type: ApplicationFiled: October 11, 2010Publication date: January 27, 2011Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT, LLCInventor: Claudia Schärer-Brodbeck
-
Patent number: 7833703Abstract: An in vivo method for the construction of randomized gene libraries and/or domain replacement in gene libraries by homologous recombination using a Kluyveromyces lactis killer toxin, in particular the (?-subunit of the K. lactis killer toxin, as negative selection marker is described. The use of the (?-subunit of K. lactis as negative selectable marker increases the percentage of randomized clones.Type: GrantFiled: April 11, 2003Date of Patent: November 16, 2010Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventor: Claudia Schärer-Brodbeck